Zhang Xiaowen, Sun Jie, Han Wenqing, Jiang Yaqiu, Peng Shiqiao, Shan Zhongyan, Teng Weiping
The Endocrine Institute and The Liaoning Provincial Key Laboratory of Endocrine Diseases, Department of Endocrinology and Metabolism, The First Hospital of China Medical University, No. 155 Nanjing North Street, Shenyang, Liaoning, China.
J Diabetes Res. 2016;2016:5928726. doi: 10.1155/2016/5928726. Epub 2016 Sep 29.
. Type 2 deiodinase (Dio2) is an enzyme responsible for the conversion of T4 to T3. The Thr92Ala polymorphism has been shown related to an increased risk for developing type 2 diabetes mellitus (T2DM). The aim of this study is to assess the association between this polymorphism and glycemic control in T2DM patients as marked by the HbA1C levels. The terms "rs225014," "thr92ala," "T92A," or "dio2 a/g" were used to search for eligible studies in the PubMed, Embase, and Cochrane databases and Google Scholar. A systematic review and meta-analysis of studies including both polymorphism testing and glycated hemoglobin (HbA1C) assays were performed. . Four studies were selected, totaling 2190 subjects. The pooled mean difference of the studies was 0.48% (95% CI, 0.18-0.77%), indicating that type 2 diabetics homozygous for the Dio2 Thr92Ala polymorphism had higher HbA1C levels. . Homozygosity for the Dio2 Thr92Ala polymorphism is associated with higher HbA1C levels in T2DM patients. To confirm this conclusion, more studies of larger populations are needed.
2型脱碘酶(Dio2)是一种负责将T4转化为T3的酶。Thr92Ala多态性已被证明与2型糖尿病(T2DM)发病风险增加有关。本研究的目的是评估这种多态性与T2DM患者血糖控制之间的关联,以糖化血红蛋白(HbA1C)水平为指标。使用“rs225014”“thr92ala”“T92A”或“dio2 a/g”等术语在PubMed、Embase、Cochrane数据库和谷歌学术中搜索符合条件的研究。对包括多态性检测和糖化血红蛋白(HbA1C)测定的研究进行了系统评价和荟萃分析。选择了四项研究,共2190名受试者。这些研究的合并平均差异为0.48%(95%CI,0.18 - 0.77%),表明Dio2 Thr92Ala多态性纯合子的2型糖尿病患者HbA1C水平更高。Dio2 Thr92Ala多态性纯合子与T2DM患者更高的HbA1C水平相关。为证实这一结论,需要更多对更大人群的研究。